All of the newly diagnosed glioblastoma multiforme patients enrolled in a Phase 1 clinical trial at the University of Alabama at Birmingham have exceeded both their median and expected progression-

In a study of patients with locally advanced mismatch repair–deficient (dMMR) rectal cancer, 6 months of treatment with the anti–PD-1 agent dostarlimab-gxly alone led to clinical complete responses